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Magnetometry analysis of brain tissue sub-samples from two neuroferritinopathy patients provides a preliminary indication that the amount of
magnetic iron compounds associated with this rare disease is significantly larger than in age/sex-matched controls. The primary iron compounds
contributing to the remnant magnetization of the tissue above 50 K and at body temperature are both blocked and superparamagnetic (SPM)
biogenic magnetite (Fe3O4) and/or maghemite (γ-Fe2O3). The concentration of SPM magnetite is significant and appears to be proportional to the
concentration of ferritin, which varies with progression of the disease. The mutated ferritin protein appears to be responsible for the presence of
iron oxide nano-particules, which in turn could be responsible for extensive damage in the brain.
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Neuroferritinopathy (NF) is a rare genetic disorder resulting
directly from a known mutation in the gene encoding for the
ferritin light polypeptide. NF has a late onset at ca. 40 years of
age [1], and results in the accumulation of aggregates of ferritin-
like clusters and iron in the basal ganglia and also throughout the
brain and is also often associated with a low serum ferritin level
[2]. Magnetic resonance imaging (MRI) is currently used to
confirm the location and amount of iron deposition [2,3] of NF
pathology by mapping iron concentrations.
Although a malfunction in the way that ferritin handles iron is
at the root of NF, the specific iron compounds associated with the
disease remain unknown [1]. Understanding which iron com-⁎ Corresponding author.
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doi:10.1016/j.bbadis.2006.09.011pounds are present is also important for determining the
potential mechanisms of neuronal damage. It is well known
that Ferrous (Fe2+) iron can promote free radical damage via the
Fenton reaction. The magnetic iron biomineral magnetite is a
mixed-valence iron oxide providing a potential source of redox-
active ferrous iron. In addition, biogenic magnetite may also
generate free radicals via triplet state stabilization due to the
strong magnetic fields associated with it [4–6].
The study of NF is highly relevant to other diseases, such as
Alzheimer's, Parkinson's and Huntington's diseases. A major
feature of virtually all neurodegenerative diseases is the accumu-
lation of excess iron. This association was first discovered in
Alzheimer's disease more than 50 years ago [7] and it is thought
that iron and other metals promote pathogenesis through
oxidative stress [8–12]. This is particularly important for ferrous
iron as its presence can lead to radical production via the Fenton
reaction. However, it is only within the past few years that
advances in the techniques used to study brain iron have started
to lead to a better understanding of the specific iron compounds
present and the brain structures with which they are associated
Fig. 1. The isothermal remanence of magnetization and their empirical fit to Eq.
(1), for sample 1 fraction 1 at 5 K (■) and 50 K (●), and for sample 2 fraction 1
at 5 K (□) and 50 K (○).
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progress in this area using modified staining techniques [16,17].
They have demonstrated that redox-active iron is closely
associated with AD plaques and neurofibrillary tangles. This
work has demonstrated that lesion-associated iron is distinct
from iron sequestered in ferritin and has provided indirect evi-
dence of the presence of Fe(II) in AD tissue. Other groups have
used transmission electron microscopy and synchrotron X-ray
analysis to demonstrate that Fe2+-bearing iron oxides are
associated with pathogenic tissue in AD [14,18,19].
For most of these diseases, however, the underlying patho-
genic mechanism is not known. By examining related neuro-
degenerative disorders, such as NF – which is well characterized
and arises from a specific genetic defect –wemay be able to shed
light on the potential role of iron in the pathogenesis of other, more
common conditions. Therefore, in order to characterize and
identify specific iron oxides associated with neuroferritinopathy,
we have evaluated the magnetic properties of brain tissue samples
from two NF cases using highly sensitive Superconducting
Quantum Interference Device (SQUID) magnetometry.
2. Materials and methods
Fresh frozen neuroferritinopathy brain tissue samples were obtained from
the Newcastle Brain Tissue Resource at the Institute for Ageing and Health,
University of Newcastle. The horse spleen ferritin was purchased from
Biogenesis and was freeze-dried prior to SQUID magnetometry measurement.
Five brain tissue samples of ca. 0.7 g from the basal ganglia, were taken from
two neuroferritinopathy female subjects of ca. 70 years of age. (Given the rarity
of neuroferritinopathy, the exact ages of the patients in this study are not
published to preserve anonymity.) All sampleswere sub-sectionedwith a ceramic
knife, stored at −80 °C, and subsequently freeze-dried. Each freeze-dried sub-
sample was introduced into a plastic straw and pressed into a pellet 4 mm high
and 5 mm in diameter using a custom-made, non-magnetic press following
procedures developed in our laboratory [13,20]. Control samples were taken
post-mortem from the hippocampus of three females (mean age=77). Samples
were frozen and measured without tissue fixation.
A change in iron metabolism associated with neurodegenerative diseases is
believed to lead to the formation of iron oxides with distinct magnetic properties
[18,19,21,22]. Therefore, the measurement of the magnetic properties of all
samples were characterized using a Quantum Design MPMS-7 (SQUID)
magnetometer. Potential iron contamination has been examined by our group
and the tissues were handled accordingly [23].
The performed measurements included isothermal remnant magnetization
(IRM), a measurement which probes the ability of a material to retain its
magnetization in the absence of an external field, following step-wise exposure
to an increasingly higher fields.
The temperature dependence of magnetization (M vs. T) measured upon
warming, after both cooling the sample in zero field (Zero-field-cooled; ZFC)
and in an applied field (Field-cooled; FC) provides information on the magnetic
blocking temperatures for magnetic compounds within the tissue and may be
compared to horse spleen ferritin, which has been well characterized and is
widely used as an analogue for non-pathogenic ferrihydrite/ferritin [24–26]. A
more detailed analysis of the M vs. T measurements, looking at the difference in
magnetization between the FC and the ZFC curve, can also reveal the presence
of superparamagnetic nanoparticles.
Finally, because it has been hypothesized that a mishandling of iron by the
ferritin protein may result in the formation of magnetite under pathogenic
conditions related to neurodegeneration [21,22,27] and because magnetite
nanoparticles have been identified by Quintana et al. [19], qualitative thermal
decay of remanence (TDR) measurements were performed in order to check for
the presence of the Verwey transition. This is a crystallographic transformation
leading to a loss of magnetization upon warming at ca. 120 K which is diagnostic
of the presence of magnetite [28]. Conventionally the decay of the remnantmagnetization in TDRmeasurements is shown upon warming. For identification
purpose and in order to gain in sensitivity, the measurement was performed upon
cooling. The sample was exposed to a magnetic field of 1 T at 170 K, above the
Verwey transition, the magnetic field was then quenched, and the remanent
magnetization was measured upon cooling.3. Results
3.1. IRM curves at 5 and 50 K
IRM measurements at 50 K, shown in Fig. 1, reveal blocked
particles which reach their saturation magnetization at ca.
300 Oe, a typical feature of magnetite (Fe3O4) and/or its oxida-
tion product maghemite (γ-Fe2O3) with a diameter larger than
ca. 13 nm [29,30]. The 5 K IRM curves, also shown in Fig. 1, do
not reach saturation and highlight the presence of an
antiferromagnetic material [31,32] with magnetization beha-
viour consistent with ferrihydrite, the most abundant magneti-
cally ordered iron species in human tissues.
3.2. IRM of HSF at 5 K
Comparison to ferritin standards allows for the quantification
of the various magnetic iron-containing species in the tissue
samples. The 5 K IRM curve of HSF shown in Fig. 2 is the
measured curve from which a trivial, blocked magnetite contri-
bution measured at 30 K of ca. 0.01% in mass was subtracted
according to the same procedure as the one used below. The
obtained empirical fit of this IRM curve to a second-degree
polynomial [2.142×10−5H–6.407×10−10 H2] is used as a
reference in other fits.
3.3. Quantitative analysis of IRM curves
The fit of any IRM curve measured on biological tissue is
likely to contain a blocked magnetite contribution which can be
Fig. 2. IRM curve of HSF measured at 5 K and fit to a second-degree
polynomial: 2.142×10−5H–6.407×10−10 H2.
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(1) with the first term only). At 5 K, a non-saturating
contribution from ferritin will be modelled with our standard
second-degree polynomial, where only the ferritin fraction is fit.
At 5 K, a third contribution to the remanence arises from
magnetite particles ordering magnetically between 50 and 5 K
and this contribution is also empirically fit to a Langevin
function which appears in the second term of Eq. (1). The IRM
curves are therefore fit to a three term empirical expression
displayed in Eq. (1),
IRM5K ¼ fB Ms2 Coth
l1H
kT
 
 kT
l1H
 
þ fSPM MS2 Coth
l2H
kT
 
 kT
l2H
 
þ f ftn 2:142 105H  6:407 1010H2
  ð1Þ
whereMs/2 is the saturation magnetization in emu/g assuming a
uniaxial non-interacting assembly of particles [33], μ1 and μ2
are empirical parameters, and fB fSPM and fFTN are the respectiveTable 1
IRM measurements at 1 T of neuroferritinopathy samples
Patient-fraction IRMsat,50K, μemu/g(WT) [
n
50 K 150 K 300 K
1-1 6.3 a 1.9 – 1
1-2 – 2.8 –
1-3 – 3.4 –
2-1 5.0 a 2.6 – 1
2-2 – 6.1 – 1
Controls – – 0.6
– – 0.6
– – 1.3
a Numbers based on an empirical fit of an IRM curve rather than a measureme
measurements and on the variance of the refined parameter for sample 1-1 and 2-1.fractions of blocked magnetite, SPM magnetite and ferritin
expressed in g/gWet Tissue. The first term is fit on its own using
the 50 K IRM data and constrained to its value in the analysis of
the 5 K data.
The various contributions are distinct from each other and
allow an accurate quantification of the concentration of ferri-
tin, magnetite that blocks at 50 K, and smaller magnetite
particles which order magnetically between 50 and 5 K.
Such detailed analysis was performed on patient 1 fraction
1 and patient 2 fraction 1 and the results are reported in
Table 1. As expected, ferritin is more abundant by three
orders of magnitude. The blocked magnetite level mea-
sured in neuroferritinopathy tissue is between 57 and
128 ng/gWet Tissue (96±32), higher than is normally mea-
sured in age/sex matched freeze-dried control tissues from
the same region of the brain (12–27 ng/gWet Tissue), as
reported in Table 1. The concentration of SPM magnetite
particles appears to vary with the concentration of ferritin
which, in turn, varies with the evolution of the disease.
SPM magnetite concentrations were of the order of 50 to
100 ng/g, bringing the total amount of magnetite in the
tissue to 100–200 ng/g.
3.4. SPM particles
Additional evidence of the presence of these SPM mag-
netite particles is given in the field cooled and zero-field
cooled results measured in 200 Oe and is shown in Fig. 3.
The shape of the FC and ZFC curve in Fig. 3 is similar to
those observed in horse spleen ferritin [24–26] but the diffe-
rence between the FC and ZFC curves is significantly
different. For ferritin, this difference decreases sharply from
5 to 25 K and is trivial at higher temperatures [24–26]. The
difference between the FC and ZFC curve exhibit a rapid
decrease of the magnetization between 5 and 25 K which is
characteristic of ferritin. In order to remove any ferritin con-
tribution from the magnetization shown in the inset of Fig. 3,
the difference curve of FC-ZFC was plotted between 25 and
300 K. The observed non-trivial magnetization is compatible
with SPM or blocked magnetite with a coercivity larger than
200 Oe, thereby reinforcing conclusions drawn from the IRM
measurements.MagnBl],
g/g(WT)
[MagnSPM],
ng/g(WT)
[Ferritin],
μg/g(WT)
[Ferritin]/
[MagnSPM]
28[4] a 96[9] a 286[7] a 2.98 a
57[3] – – –
69[17] – – –
02[4] a 44[14] a 132[6] a 3.00 a
24[21] – – –
12 – – –
12 – – –
27 – – –
nt at saturation. The error is based on an instrumental error for single point
Fig. 4. The thermal decay of remanence measured on patient 2 fraction 2,
through the Verwey transition, in zero-field, and upon cooling; after having
applied a field of 1 T.
Fig. 3. Temperature dependence of the magnetization of patient 1 fraction 1,
measured in zero-field cooled and field cooled conditions with a field of 200 Oe.
The inset shows the difference between the two curves above 25 K where there
is no contribution from ferritin.
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The field at which the remnant magnetization saturates
suggests the presence of magnetite/maghemite. The observa-
tion of a strong Verwey transition [28] at ca. 125 K in the TDR
measurement of one of the two samples reported shown in
Fig. 4 confirms that at least part of the measured magnetiza-
tion in that sample is due to magnetite. Measurement on the
other samples was a lot noisier and inconclusive because of a
low signal. Maghemite, a ferric iron oxide with magnetic
properties similar to magnetite, is generally formed via the
oxidation of ferrous iron in magnetite and could be responsible
for a possible absence of the Verwey transition in some of the
samples.
4. Discussion
While some of the magnetic measurement techniques
employed here cannot unequivocally identify magnetite, the
magnetization data is completely consistent with this iron oxide
or its oxidation product, maghemite. In addition, the presence of
the Verwey transition measured in one of the two samples is
clearly indicative of magnetite. Therefore, the preliminary
results reported here indicate that in Neuroferritinopathy, the
malfunction of the ferritin light polypeptide appears to lead to
the formation of SPM magnetite. The presence of magnetite
may reduce the bioavailability of iron, and potentiate free
radical production via the Fenton reaction and/or triplet state
stabilization [4–6]. The characterization of intermediate
magnetic iron compounds associated with the mineral bio-
transformation of iron, which can lead to the formation of
magnetite, in neurodegenerative disorders such as Neuroferri-
tinopathy and others can be performed by SQUID magneto-
metry [13,24–26] and nuclear magnetic resonance [15,34].
Using such knowledge, it may be possible to develop new pulsesequences for MRI-based early diagnosis. This is particularly
important for diseases such as Alzheimer's, where treatments in
development are aimed primarily at slowing or halting
progression of the disease rather than reversing its effects. In
this case, diagnosis and intervention at the earliest possible
stage should lead to better treatment outcomes.
The coercivity data presented here, as well as TEM imaging
conducted on magnetic extracts from hippocampal tissue [6,21],
indicate that larger, blocked magnetite particles are present
within the tissue as well. The origin of these remains unknown
but they may grow from nucleation sites within ferritin followed
by a breakdown of the protein shell. While in situ TEM analysis
would help to clarify this conundrum, the low concentration of
blocked magnetite in the tissue (on the order of -ng/g of wet
tissue) means that finding them in tissue sections is not a trivial
exercise. This is the main reason for the recent development of
automated scanning techniques which employ micro-focused
synchrotron X-ray analysis [15,35].
Recent electron microscopy analysis of ferritin from
Alzheimer's tissue indicates that cubic, mixed-valence iron
oxides may be forming within the protein related to
pathogenesis [19,36]. This provides an indication that
neuroferritinopathy may be a good model system for
studying the effects of disruptions in ferritin function in
other neurodegenerative diseases.
Although large crystals of biogenic magnetite have pre-
viously been observed [21] in the human brain, the origin of
such large crystals remains unknown.
The presence of SPM magnetite in AD brain tissues has
previously been reported and appears to originate from the
biomineralization of the ferrihydrite core of Ferritin as a possible
pathway for the formation of larger magnetite particles
[13,14,18–22]. In this study, the presence of SPM magnetite is
correlated with the amount of ferrihydrite suggesting that a mal-
function of ferritin may play a role in the magnetite biomi-
neralization process. Because of the rarity of the disease and the
paucity of available data these results should be considered as
preliminary at this stage.
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